Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
NCT02002312
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
14
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
DRUG:
Lu-177-DOTA-girentuximab
Sponsor
Radboud University Medical Center